BioSig to Present at Heart Rhythm 2022
April 19 2022 - 9:10AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) a medical technology company advancing electrophysiology
workflow by delivering greater intracardiac signal fidelity through
its proprietary signal processing platform, today announced that
the Company would be exhibiting at Heart Rhythm 2022, due to take
place on April 29 – May 1, 2022 at the Moscone Center in San
Francisco, CA.
Clinical observations collected by BioSig’s PURE EP(TM) System
will be featured in a poster presentation, titled Elimination Of
Harmonic Ringing In Intracardiac Signals Using Dynamic Algorithmic
Notch Filtering, and co-authored by Amin Al-Ahmad, M.D.; G Joseph
Gallinghouse M.D.; Thomas Ladas, M.D.; Domenico Della Rocca M.D.;
Matthew Dare; and Andrea Natale, M.D., of St David’s St. David’s
Medical Center in Austin Texas. The presentation session will take
place at Pod #12 on Sunday May 1st, 2022.
During the event, BioSig will be exhibiting at booth 1071. The
Company’s executive leadership, clinical and commercial teams will
host a series of technology demonstrations, including features of
its newly released PURE EP(TM) NOVA-5 Software. Enhanced with
NOVA-5 Software, the PURE EP(TM) System delivers a new standard in
signal processing, offering greater customization and smarter
workflows.
In addition, the company will provide an outlook into current
developments and the future of its signal processing technology
during a presentation series titled, Signal Processing Pipeline
Discovery on Friday, April 29th and Saturday, April 30th.
Physicians attending the conference may reserve sessions by
appointment.
The PURE EP(TM) System is an FDA 510(k) cleared non-invasive
class II device that aims to enhance physician workflow and
increase procedural efficiency and efficacy in cardiac
electrophysiology. To date, 75 physicians have
completed more than 2,200 patient cases with the
PURE EP(TM) System.
Clinical data acquired by the PURE EP(TM) System in a
multi-center study at Texas Cardiac Arrhythmia Institute at St.
David's Medical Center, Mayo Clinic Jacksonville, and Massachusetts
General Hospital was recently published in the Journal of
Cardiovascular Electrophysiology and is available electronically
with open access via the Wiley Online Library. Study results
showed 93% consensus across the blinded reviewers with a 75%
overall improvement in intracardiac signal quality and confidence
in interpreting PURE EP™ signals over conventional sources.
About Heart Rhythm 2022Heart Rhythm 2022 is a
hub for innovation and discoveries in medicine. The event serves as
a platform for innovators to create and cultivate collaborative
discussions with domestic and international leaders across the
field of cardiac arrhythmia. This year’s event will feature over
250 expert-led sessions, education, ground-breaking science, and
game-changing innovations.
Heart Rhythm 2022 is Heart Rhythm Society program. Heart Rhythm
Society (HRS) is a 501c3 international nonprofit organization with
a mission to improve the care of patients by promoting research,
education, and optimal health care policies and standards. Founded
in 1979, HRS is a leading resource on cardiac pacing and
electrophysiology. This specialty organization represents medical,
allied health, and science professionals from more than 70
countries specializing in cardiac rhythm disorders
(www.heartrhythm.com).
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE
EP(TM) System is a computerized system intended for
acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024